NEUROENDOCRINE TUMORS

This study is testing a different way of taking the drug cabozantinib to see if it can reduce severe side effects while still controlling cancer growth. It involves 111 adults with advanced kidney cancer or neuroendocrine tumors. The goal is to find a dosing schedule that patient…

This early-phase study tests a new drug called Sapu003 in 27 adults with advanced solid tumors (like breast, kidney, or liver cancer) that are sensitive to mTOR-targeted therapy. The main goal is to find the safest dose and check for side effects. Participants receive Sapu003 wee…

This study tests a new drug called CRN09682 in people with advanced neuroendocrine tumors and other solid tumors that have spread and are getting worse. The goal is to find the safest dose and see if the drug can shrink tumors or slow their growth. About 150 adults will take part…

This early-stage study tests a new drug called BL-M14D1 in about 22 people with advanced small cell lung cancer, neuroendocrine tumors, or other solid tumors that have spread and no longer respond to standard treatments. The main goals are to check the drug's safety, find the bes…

This early-phase trial tests a virus that targets and kills cancer cells (SVV-001) combined with two immunotherapy drugs (nivolumab and ipilimumab) in adults with advanced neuroendocrine tumors or carcinomas that have worsened after standard treatment. The main goals are to find …

This early-phase trial tests a new drug called ADCT-701 in about 70 adults with rare neuroendocrine tumors, adrenal cancer, or malignant nerve sheath tumors that have not responded to standard treatments. The drug is given through an IV and aims to deliver a cancer-killing agent …

This study tests a radioactive drug called Lu-177-DOTATATE in people with rare tumors (pheochromocytoma or paraganglioma) that cannot be surgically removed. The goal is to see if the drug can slow or stop tumor growth and to check its safety. Participants receive four doses about…

This study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors of the gut or pancreas that have grown after prior treatment with a standard radioactive therapy. The goal is to see if RYZ101 can slow tumor growth better than other available treatments. Abo…

This study tests a combination of two drugs (lenvatinib and pembrolizumab) in people with a rare, aggressive type of neuroendocrine tumor called well-differentiated grade 3 (WD G3 NET). The goal is to see if the treatment can shrink or control the tumors. About 29 adults with adv…

This study tests whether combining Lutathera (a radioactive drug) with Olaparib (a targeted pill) can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive the treatment over several months and be monitored for s…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control tumors for at least 12 months. About 28 adults who have not responded to standard treatments will take part.

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…

This early-stage study tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The main goals are to find the safest dose and schedule, and to see if the drug can shrink tumors. About 10…

This study looks at how well the drug cabozantinib works and how safe it is for adults with neuroendocrine tumors (NETs) that have continued to grow despite at least one prior treatment. About 150 participants in Germany and Austria will be followed during their routine care. Doc…

This study tests if a targeted radiation therapy (177Lu-edotreotide) works better than a standard drug (everolimus) for people with advanced neuroendocrine tumors of the lung or thymus. About 170 adults with these rare tumors will receive either treatment, and researchers will tr…

This study tests a new treatment called CHM-2101 for people with advanced gastrointestinal cancers (stomach, colon, or neuroendocrine tumors) that have stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to recognize and attack canc…

This study tests whether personalizing a type of radiation therapy (PRRT) for neuroendocrine tumors works better and is safer than the standard one-size-fits-all approach. About 300 adults with advanced, slow-growing neuroendocrine tumors that are no longer responding to other tr…

This study looks at how well peptide receptor radionuclide therapy (PRRT) works for people with neuroendocrine tumors that started in the stomach, intestines, or pancreas. Researchers will track 50 patients to see how they respond to treatment, how long they live, and what side e…

This early-phase study tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors. It is a first-in-human trial, so the main focus is on …

This study tests a drug called tirapazamine given with a procedure that blocks blood flow to liver tumors (embolization). The goal is to find the safest dose and see how well it shrinks tumors. It is for people with liver cancer or certain metastatic tumors that have spread to th…

This study is testing a drug called surufatinib in 350 adults with advanced neuroendocrine tumors, a rare type of cancer. The goal is to see how well the drug controls the disease and what side effects occur when used in regular medical practice. Participants take the drug daily …

This study tests a personalized gene therapy for people with metastatic cancers that haven't responded to standard treatments. Doctors take a patient's own white blood cells, genetically engineer them in a lab to recognize and attack unique mutations in their tumor, and then infu…

This study looks at whether giving two more doses of Lutathera (a targeted radiation therapy) can help control intestinal neuroendocrine tumors that have started growing again after initial treatment. About 146 adults whose tumors were stable for at least 12 months after their fi…

This early-stage trial tests whether taking a drug called ASTX727 for 5 days before Lutathera treatment can make neuroendocrine tumors more sensitive to the therapy. About 27 adults with metastatic neuroendocrine tumors will receive the combination. The goal is to see if this app…

This early-stage trial tests a new drug, NN3201, designed to attack cancer cells that have a specific marker called c-Kit. The study includes people with advanced or spreading cancers like gastrointestinal stromal tumors (GIST), small-cell lung cancer, and others. The main goal i…

This study tests whether adding a type of internal radiation (Yttrium-90) to a standard chemotherapy regimen (Capecitabine and Temozolomide) can better control neuroendocrine tumors that have spread to the liver and cannot be surgically removed. About 70 adults with grade 2 or 3 …

This study tests a new radioactive drug called Terbium-161 DOTATATE in 20 adults with advanced neuroendocrine tumors that have stopped responding to standard treatment. The drug delivers radiation directly to cancer cells while sparing healthy tissue. The goal is to see if it can…

This study is testing whether a new blood test that measures a protein called hPG80 can help detect neuroendocrine tumors (NETs) earlier in people with MEN1, a rare genetic condition that raises the risk for these tumors. About 297 participants with MEN1 will give blood samples, …

This study tests a new radioactive tracer called 68Ga-HA-DOTATATE for PET/CT scans in people with known or suspected neuroendocrine tumors. The goal is to see if it is safe and more accurate than older imaging methods. About 600 participants will be enrolled to measure how well t…

This study is testing a special PET scan (18F-DOPA) to see if it can better detect and measure several conditions, including congenital hyperinsulinism in children, neuroblastoma, neuroendocrine tumors, Parkinson's disease, Lewy body dementia, and brain tumors. About 800 children…

This study is testing a new radioactive tracer called 89Zr-TLX250 to see if it can better detect liver cancers (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) and pancreatic neuroendocrine tumors on PET-CT scans. About 60 adults with these cancers will receive the …

This study tests whether guarana, a natural plant extract, can improve fatigue in people with neuroendocrine tumors or gynecologic cancers. About 86 adults will take guarana or a placebo for up to 42 days, and researchers will measure changes in fatigue and quality of life. The g…

This study is testing whether a special PET scan (Detectnet) can help doctors plan a type of radiation therapy (Lutathera) more safely for people with neuroendocrine cancer. Ten participants will get extra scans to see if the PET scan can accurately predict where the radiation go…

This study follows people with von Hippel-Lindau (VHL) disease who have pancreatic tumors or cysts. The goal is to understand how these growths change over time and to see if a special PET scan (68-Gallium DOTATATE) can find tumors better than standard scans. About 740 participan…

This study is testing whether an artificial intelligence (AI) tool can help match people with advanced cancer to the right clinical trials. Researchers will enroll up to 50,000 participants to see if the AI improves trial enrollment rates and patient outcomes. The goal is to make…

This early-phase study tests a special PET/CT scan that uses a modified tryptophan molecule to highlight tumors. Researchers want to see if this scan can better distinguish cancer from healthy tissue in people with brain tumors, breast cancer, neuroendocrine tumors, or rectal can…

This study is creating a large database of clinical information and blood samples from 350 adults receiving metabolic radiotherapy for thyroid cancer, prostate cancer, or neuroendocrine tumors. The goal is to provide researchers with valuable data to better understand these treat…

This study follows 300 adults with neuroendocrine tumors (including adrenocortical carcinoma) over their lifetime to understand how these rare cancers behave. Participants provide blood, urine, and tumor samples, and have yearly check-ups. The goal is to gather information and sa…

This study looks at whether follow-up care for people with rare tumors can be done just as well by a nurse remotely as by a doctor in person. About 88 adults recently diagnosed with a rare tumor will be randomly assigned to either in-person doctor visits or remote nurse check-ins…

This study looks at how things like age, sex, tumor grade, and location affect how well treatments work for people with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NENs). Researchers will track 450 adults who have received standard therapies like somatos…

This study is creating a large database of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand what causes cancer, how it progresses, and how to improve p…